NCT06449092

Brief Summary

  1. 1.To detect the significance of remenant cholesterol in detection severity of MAFLD
  2. 2.To detect the significance of carotid intima-media thickness in MAFLD

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 3, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 7, 2024

Completed
7 months until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

June 7, 2024

Status Verified

June 1, 2024

Enrollment Period

1 year

First QC Date

June 3, 2024

Last Update Submit

June 6, 2024

Conditions

Detect the Significance of Remnant Cholesterol in Detection Severity of MAFLD

Outcome Measures

Primary Outcomes (2)

  • To detect the significance of remnant cholesterol in detection severity of MAFLD

    lipid profile in MAFLD patients to detect remnant cholesterol

    From Jan 2025 to Jan 2026

  • To detect the relationship between carotid intima-media thickness and remnant cholesterol in MAFLD and prediction of cardiovascular effect.

    color doppler and echocardiography in MAFLD patients

    From Jan 2025 to Jan 2026

Interventions

Lipid profileDIAGNOSTIC_TEST

carotid intima media thickness

Also known as: color doppler

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study will include patients presented to Fibroscan clinic, Internal medicine department at Assiut University hospitals within 1 year

You may qualify if:

  • The study will include adult patients (≥18 years) presented to fibroscan clinic and diagnosed as MAFLD.

You may not qualify if:

  • Patients Known previous cardiac disease ( cardiovascular disease, heart failure, arrhythmia )
  • Patients Known liver cirrhosis
  • septic patients
  • Patients have malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

RECRUITING

Central Study Contacts

Ahmed Kh Nazier

CONTACT

01005897058ak0555012@gmail.com

Marwa Mo Mahmoud

CONTACT

01000580208marwaabokresha@aun.edu.eg

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ahmed Khaled Mohammed

Study Record Dates

First Submitted

June 3, 2024

First Posted

June 7, 2024

Study Start

January 1, 2025

Primary Completion

January 1, 2026

Study Completion

January 1, 2026

Last Updated

June 7, 2024

Record last verified: 2024-06

Locations

EG(1)